GSA Capital Partners’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

GSA Capital Partners’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-11,862	Closed	-$109K	–	2026
2023 Q3	$109K	Buy	11,862 +2,339	+25%	+$47K	0.01%	1378
2023 Q2	$201K	Buy	9,523 +3,006	+46%	+$92.6K	0.02%	1268
2023 Q1	$175K	Buy	6,517 +3,916	+151%	+$182K	0.02%	1285
2022 Q4	$92K	Buy	+2,601	New	+$312K	0.01%	1318
2022 Q1	–	Sell	-6,166	Closed	-$960K	–	1930
2021 Q4	$960K	Buy	6,166 +1,226	+25%	+$237K	0.12%	223
2021 Q3	$990K	Buy	4,940 +2,276	+85%	+$541K	0.1%	313
2021 Q2	$681K	Buy	2,664 +1,778	+201%	+$444K	0.08%	442
2021 Q1	$235K	Sell	886 -3,632	-80%	-$1.14M	0.04%	805
2020 Q4	$1.67M	Buy	4,518 +235	+5%	+$67.4K	0.27%	42
2020 Q3	$1.05M	Buy	4,283 +3,523	+464%	+$1.1M	0.17%	90
2020 Q2	$219K	Buy	+760	New	+$224K	0.12%	298
2020 Q1	–	Sell	-431	Closed	-$192K	–	1668
2019 Q4	$192K	Sell	431 -217	-33%	-$77K	0.02%	1269
2019 Q3	$199K	Sell	648 -883	-58%	-$287K	0.03%	1166
2019 Q2	$487K	Buy	+1,531	New	+$530K	0.05%	678

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's EIGR Position: Q4 2023 in Review

GSA Capital Partners sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2023, closing a stake of 11,862 shares — an estimated $109K sold.

GSA Capital Partners first reported a position in EIGR in Q2 2019 and held it in 14 quarters. The position peaked at $1.67M in Q4 2020. 43 funds tracked by Wall St. Rank hold EIGR as of Q4 2023.

GSA Capital Partners reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
GSA Capital Partners sold 11,862 Eiger BioPharmaceuticals, Inc. shares in Q4 2023, an estimated $109K.
GSA Capital Partners first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2019 and held it in 14 quarters.
GSA Capital Partners's Eiger BioPharmaceuticals, Inc. position peaked at $1.67M in Q4 2020.
43 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2023.

Based on GSA Capital Partners's 13F filing for Q4 2023, filed 16 Feb 2024.